218 related articles for article (PubMed ID: 37506139)
21. Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases.
Biagioli M; Mencarelli A; Carino A; Cipriani S; Marchianò S; Fiorucci C; Donini A; Graziosi L; Baldelli F; Distrutti E; Costantino G; Fiorucci S
Inflamm Bowel Dis; 2017 Dec; 24(1):123-135. PubMed ID: 29272492
[TBL] [Abstract][Full Text] [Related]
22. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
23. The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL.
Miller YI; Choi SH; Wiesner P; Bae YS
Br J Pharmacol; 2012 Nov; 167(5):990-9. PubMed ID: 22776094
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway.
Chen KH; Hsu HH; Yang HY; Tian YC; Ko YC; Yang CW; Hung CC
Int J Biochem Cell Biol; 2016 May; 74():135-44. PubMed ID: 26948651
[TBL] [Abstract][Full Text] [Related]
25. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
[TBL] [Abstract][Full Text] [Related]
26. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
27. The ubiquitous role of spleen tyrosine kinase (Syk) in gut diseases: From mucosal immunity to targeted therapy.
Gong W; Liu P; Zheng T; Wu X; Zhao Y; Ren J
Int Rev Immunol; 2022; 41(5):552-563. PubMed ID: 34355656
[TBL] [Abstract][Full Text] [Related]
28. Spleen tyrosine kinase inhibition ameliorates airway inflammation through modulation of NLRP3 inflammosome and Th17/Treg axis.
Patel D; Gaikwad S; Challagundla N; Nivsarkar M; Agrawal-Rajput R
Int Immunopharmacol; 2018 Jan; 54():375-384. PubMed ID: 29202301
[TBL] [Abstract][Full Text] [Related]
29. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
[TBL] [Abstract][Full Text] [Related]
30. High SYK Expression Drives Constitutive Activation of CD21
Keller B; Stumpf I; Strohmeier V; Usadel S; Verhoeyen E; Eibel H; Warnatz K
J Immunol; 2017 Jun; 198(11):4285-4292. PubMed ID: 28468967
[TBL] [Abstract][Full Text] [Related]
31. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases.
Ghosh D; Tsokos GC
Autoimmunity; 2010 Feb; 43(1):48-55. PubMed ID: 20001666
[TBL] [Abstract][Full Text] [Related]
32. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
33. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
34. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
35. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
36. Syk-MyD88 Axis Is a Critical Determinant of Inflammatory-Response in Activated Macrophages.
Yi YS; Kim HG; Kim JH; Yang WS; Kim E; Jeong D; Park JG; Aziz N; Kim S; Parameswaran N; Cho JY
Front Immunol; 2021; 12():767366. PubMed ID: 35003083
[TBL] [Abstract][Full Text] [Related]
37. Targeting Syk as a treatment for allergic and autoimmune disorders.
Wong BR; Grossbard EB; Payan DG; Masuda ES
Expert Opin Investig Drugs; 2004 Jul; 13(7):743-62. PubMed ID: 15212616
[TBL] [Abstract][Full Text] [Related]
38. Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK).
Wang Z; Qu S; Yuan J; Tian W; Xu J; Tao R; Sun S; Lu T; Tang W; Zhu Y
Bioorg Med Chem; 2023 Dec; 96():117514. PubMed ID: 37984216
[TBL] [Abstract][Full Text] [Related]
39. The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases.
Efferth T; Oesch F
Med Res Rev; 2021 Nov; 41(6):3023-3061. PubMed ID: 34288018
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.
Szilveszter KP; Németh T; Mócsai A
Front Immunol; 2019; 10():1862. PubMed ID: 31447854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
